Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SG2918 for injection in relapsed/refractory multiple myeloma
CTR20260123Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SG2918 in multiple myeloma (MM), sponsored by Shangjian Bio. Primary endpoints: Safety and tolerability, Dose-limiting toxicity and 1 more. Started Apr 2026; status: active.
02
Drugs
SG2918
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20260123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260123.